Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Amarin Corporation plc (NASDAQ: AMRN) shares declined percent to close at $9.56 a share Tuesday. The stock traded between $5.55 and $5.79 on volume of 11.88 million shares traded. The company announced a public offering of 21.7 million American Depositary Shares. Shares of Amarin have fallen approximately 31.0 percent year-to-date.
Get more information on Amarin and free access to the in-depth equity report at:
www.FiveStarEquities.com/AMRN
CytRx Corporation (NASDAQ: CYTR) shares soared 20.91 percent to close at $2.66 a share Tuesday. The stock traded between $2.60 and $3.20 on volume of 3.97 million shares traded. The company announced that aldoxorubicin, which is a more potent version doxorubicin, was effective in treating human brain (glioblastoma) cancer in the brains of animals. Shares of CytRx have gained approximately 42.0 percent year-to-date.
Get more information on CytRx and free access to the in-depth equity report at:
www.FiveStarEquities.com/CYTR
PharMerica Corporation (NYSE:PMC) shares dropped 7.55 percent to close at $12.86 a share Tuesday. The stock traded between $12.51 and $13.55 on volume of 508,136 shares traded. Barclays has recently downgraded the company rating to “underweight” from “equal weight” and currently has a price target of $12.00 on the stock. Shares of PharMerica have declined approximately 9.7 percent year-to-date.
Get more information on PharMerica and free access to the in-depth equity report at:
www.FiveStarEquities.com/PMC
Ixia (NASDAQ: XXIA) shares plunged 19.39 percent to close at $14.30 a share Tuesday. The stock traded between $13.31 and $14.99 on volume of 5.68 million shares traded. The company expects revenues for the second quarter to be in range of $114 million to $116 million, down from their previous guidance of $119 million to $122 million. Shares of Ixia have fallen approximately 15.8 percent year-to-date.
Get more information on Ixia and free access to the in-depth equity report at:
www.FiveStarEquities.com/XXIA
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
[email protected]